{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:12:25Z","timestamp":1790759545825,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T00:00:00Z","timestamp":1567209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T00:00:00Z","timestamp":1567209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Institut national de la sant\u00e9 et de la recherche m\u00e9dicale\u2013Direction de l\u2019Hospitalisation et de l\u2019Organisation des Soins"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Dipeptidyl peptidase 3 (DPP3) is a protease involved in the degradation of cardiovascular mediators. Its administration has been shown to be associated with impaired cardiac contraction and kidney haemodynamics while its inhibition restored cardiac contraction in a pre-clinical model of severe heart failure in mice. Circulating DPP3 (cDPP3) was found to be elevated in shock. The present study aims to assess the association between cDPP3 and worsening haemodynamics, namely refractory shock, in a cohort of cardiogenic shock (CS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This is an ancillary study of OptimaCC, a prospective, double-blind, multicentre, randomized study assessing efficacy and safety of catecholamines in 57 patients with CS after acute myocardial infarction. cDPP3 was measured in plasma at inclusion, 24\u2009h, 48\u2009h, and 72\u2009h, and haemodynamic and biological parameters were recorded at inclusion. cDPP3 values were higher in refractory CS than non-refractory CS at inclusion (median [interquartile range]; 76.1 [37.9\u2013238.7] ng\/mL vs. 32.8 [23.9\u201347.6] ng\/mL, P =\u20090.014), at 24\u2009h (P &amp;lt;\u20090.001) and up to 48\u2009h (P =\u20090.027). Furthermore, cDPP3 at inclusion discriminated CS patients who did develop refractory shock vs. non-refractory with an area under the curve of 0.73 (95% confidence interval [CI] 0.55\u20130.92). The high cDPP3 group (cDPP3 \u226559.1 ng\/mL) at inclusion had a higher Simplified Acute Physiology Score II (SAPS II), lower cardiac index and lower estimated glomerular filtration rate. More importantly, in CS patients with high cDPP3 at inclusion, those who rapidly decreased cDPP3 at 24\u2009h exhibited a striking reduction in the occurrence of refractory shock and death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In CS patients, cDPP3 gives an early prediction of outcome, including development of refractory status and\/or survival.<\/jats:p>\n                    <jats:p>Clinical Trial Registration: clinicaltrials.gov Identifier NCT01367743<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.1600","type":"journal-article","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T09:52:02Z","timestamp":1567245122000},"page":"279-286","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Circulating Dipeptidyl Peptidase 3 and Alteration in Haemodynamics in Cardiogenic Shock: Results from the OptimaCC Trial"],"prefix":"10.1093","volume":"22","author":[{"given":"Koji","family":"Takagi","sequence":"first","affiliation":[{"name":"Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), University of Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Blet","sequence":"additional","affiliation":[{"name":"Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), University of Paris , Paris ,","place":["France"]},{"name":"Department of Anaesthesiology, Burn and Critical Care, University Hospitals Saint-Louis\u2013Lariboisi\u00e8re, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Levy","sequence":"additional","affiliation":[{"name":"Intensive Care Medicine Brabois, CHRU de Nancy, INSERM U1116, 54511, Vandoeuvre-les-Nancy, Universit\u00e9 de Lorraine , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Deniau","sequence":"additional","affiliation":[{"name":"Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), University of Paris , Paris ,","place":["France"]},{"name":"Department of Anaesthesiology, Burn and Critical Care, University Hospitals Saint-Louis\u2013Lariboisi\u00e8re, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feriel","family":"Azibani","sequence":"additional","affiliation":[{"name":"Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), University of Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Feliot","sequence":"additional","affiliation":[{"name":"Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), University of Paris , Paris ,","place":["France"]},{"name":"Department of Anaesthesiology, Burn and Critical Care, University Hospitals Saint-Louis\u2013Lariboisi\u00e8re, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bergmann","sequence":"additional","affiliation":[{"name":"4TEEN4 Pharmaceuticals GmbH , Hennigsdorf ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Santos","sequence":"additional","affiliation":[{"name":"4TEEN4 Pharmaceuticals GmbH , Hennigsdorf ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Hartmann","sequence":"additional","affiliation":[{"name":"4TEEN4 Pharmaceuticals GmbH , Hennigsdorf ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Gayat","sequence":"additional","affiliation":[{"name":"Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), University of Paris , Paris ,","place":["France"]},{"name":"Department of Anaesthesiology, Burn and Critical Care, University Hospitals Saint-Louis\u2013Lariboisi\u00e8re, AP-HP , Paris ,","place":["France"]},{"name":"Universit\u00e9 de Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[{"name":"Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), University of Paris , Paris ,","place":["France"]},{"name":"Department of Anaesthesiology, Burn and Critical Care, University Hospitals Saint-Louis\u2013Lariboisi\u00e8re, AP-HP , Paris ,","place":["France"]},{"name":"Universit\u00e9 de Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Kimmoun","sequence":"additional","affiliation":[{"name":"Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), University of Paris , Paris ,","place":["France"]},{"name":"Intensive Care Medicine Brabois, CHRU de Nancy, INSERM U1116, 54511, Vandoeuvre-les-Nancy, Universit\u00e9 de Lorraine , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,31]]},"reference":[{"key":"2026011721340628000_ejhf1600-bib-0001","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7326\/0003-4819-131-1-199907060-00010","article-title":"Cardiogenic shock","volume":"131","author":"Hollenberg","year":"1999","journal-title":"Ann Intern Med"},{"key":"2026011721340628000_ejhf1600-bib-0002","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/CIRCULATIONAHA.106.613596","article-title":"Cardiogenic shock: current concepts and improving outcomes","volume":"117","author":"Reynolds","year":"2008","journal-title":"Circulation"},{"key":"2026011721340628000_ejhf1600-bib-0003","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ejhf.958","article-title":"Acute kidney injury in cardiogenic shock: definitions, incidence, haemodynamic alterations, and mortality","volume":"20","author":"Tarvasm\u00e4ki","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026011721340628000_ejhf1600-bib-0004","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1208410","article-title":"Intraaortic balloon support for myocardial infarction with cardiogenic shock","volume":"367","author":"Thiele","year":"2012","journal-title":"N Engl J Med"},{"key":"2026011721340628000_ejhf1600-bib-0005","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ejhf.939","article-title":"Extracorporeal membrane oxygenation in the therapy of cardiogenic shock (ECMO-CS): the need for a better definition of refractory cardiogenic shock","volume":"20","author":"Champion","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026011721340628000_ejhf1600-bib-0006","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1161\/01.CIR.0000075927.67673.F2","article-title":"Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm","volume":"107","author":"Hochman","year":"2003","journal-title":"Circulation"},{"key":"2026011721340628000_ejhf1600-bib-0007","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00392-017-1182-2","article-title":"Trends in mechanical circulatory support use and hospital mortality among patients with acute myocardial infarction and non-infarction related cardiogenic shock in the United States","volume":"107","author":"Shah","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"2026011721340628000_ejhf1600-bib-0008","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/eurheartj\/ehv194","article-title":"Predicting survival after ECMO for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)-score","volume":"36","author":"Schmidt","year":"2015","journal-title":"Eur Heart J"},{"key":"2026011721340628000_ejhf1600-bib-0009","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00134-016-4223-9","article-title":"The ENCOURAGE mortality risk score and analysis of long-term outcomes after VA-ECMO for acute myocardial infarction with cardiogenic shock","volume":"42","author":"Muller","year":"2016","journal-title":"Intensive Care Med"},{"key":"2026011721340628000_ejhf1600-bib-0010","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s13054-016-1520-1","article-title":"The modified SAVE score: predicting survival using urgent veno-arterial extracorporeal membrane oxygenation within 24 hours of arrival at the emergency department","volume":"20","author":"Chen","year":"2016","journal-title":"Crit Care"},{"key":"2026011721340628000_ejhf1600-bib-0011","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/ejhf.260","article-title":"Clinical picture and risk prediction of short-term mortality in cardiogenic shock","volume":"17","author":"Harjola","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721340628000_ejhf1600-bib-0012","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/ejhf.1204","article-title":"Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"20","author":"Harjola","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026011721340628000_ejhf1600-bib-0013","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0002-9610(97)89552-9","article-title":"Serial blood lactate levels can predict the development of multiple organ failure following septic shock","volume":"171","author":"Bakker","year":"1996","journal-title":"Am J Surg"},{"key":"2026011721340628000_ejhf1600-bib-0014","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/17482941.2011.655293","article-title":"Lactate clearance in cardiogenic shock following ST elevation myocardial infarction: a pilot study","volume":"14","author":"Attan\u00e1","year":"2012","journal-title":"Acute Card Care"},{"key":"2026011721340628000_ejhf1600-bib-0015","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1097\/CCM.0000000000000405","article-title":"Lactate clearance is a useful biomarker for the prediction of all-cause mortality in critically ill patients: a systematic review and meta-analysis*","volume":"42","author":"Zhang","year":"2014","journal-title":"Crit Care Med"},{"key":"2026011721340628000_ejhf1600-bib-0016","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/j.1471-4159.1987.tb05700.x","article-title":"Angiotensin II inactivation process in cultured mouse spinal cord cells","volume":"48","author":"Allard","year":"1987","journal-title":"J Neurochem"},{"key":"2026011721340628000_ejhf1600-bib-0017","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1111\/j.1742-4658.2011.08275.x","article-title":"Dipeptidyl peptidase III: a multifaceted oligopeptide N-end cutter","volume":"278","author":"Prajapati","year":"2011","journal-title":"FEBS J"},{"key":"2026011721340628000_ejhf1600-bib-0018","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/HYPERTENSIONAHA.116.07471","article-title":"On endogenous angiotensin II antagonism in hypertension: The role of dipeptidyl peptidase III","volume":"68","author":"Ocaranza","year":"2016","journal-title":"Hypertension"},{"key":"2026011721340628000_ejhf1600-bib-0019","article-title":"Novel methods for the quantification of dipeptidyl peptidase 3 (DPP3) concentration and activity in human blood samples","author":"Rehfeld","year":"2018","journal-title":"J Appl Lab Med"},{"key":"2026011721340628000_ejhf1600-bib-0020","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ejhf.1601","article-title":"Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves hemodynamics","volume":"22","author":"Deniau","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026011721340628000_ejhf1600-bib-0021","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2018.04.051","article-title":"Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction","volume":"72","author":"Levy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026011721340628000_ejhf1600-bib-0022","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1001\/archinte.165.14.1643","article-title":"Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock","volume":"165","author":"Kohsaka","year":"2005","journal-title":"Arch Intern Med"},{"key":"2026011721340628000_ejhf1600-bib-0023","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJM199908263410901","article-title":"Early revascularization in acute myocardial infarction complicated by cardiogenic shock","volume":"341","author":"Hochman","year":"1999","journal-title":"N Engl J Med"},{"key":"2026011721340628000_ejhf1600-bib-0024","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1710261","article-title":"PCI strategies in patients with acute myocardial infarction and cardiogenic shock","volume":"377","author":"Thiele","year":"2017","journal-title":"N Engl J Med"},{"key":"2026011721340628000_ejhf1600-bib-0025","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.297.15.joc70035","article-title":"Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock","volume":"297","author":"The TRIUMPH Investigators","year":"2007","journal-title":"JAMA"},{"key":"2026011721340628000_ejhf1600-bib-0026","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nrcardio.2016.96","article-title":"Management of refractory cardiogenic shock","volume":"13","author":"Reyentovich","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"2026011721340628000_ejhf1600-bib-0027","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00134-018-5214-9","article-title":"Management of cardiogenic shock complicating myocardial infarction","volume":"44","author":"Mebazaa","year":"2018","journal-title":"Intensive Care Med"},{"key":"2026011721340628000_ejhf1600-bib-0028","first-page":"654708","article-title":"Therapeutic strategies for high-dose vasopressor-dependent shock","volume":"2013","author":"Bassi","year":"2013","journal-title":"Crit Care Res Pract"},{"key":"2026011721340628000_ejhf1600-bib-0029","first-page":"29","article-title":"SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019","volume":"94","author":"Baran","year":"2019","journal-title":"Catheter Cardiovasc Interv"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.1600","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.1600","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/22\/2\/279\/66112700\/eurjhf_22_2_279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/22\/2\/279\/66112700\/eurjhf_22_2_279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:34:57Z","timestamp":1768703697000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/22\/2\/279\/8385368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,31]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,8,31]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.1600","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2]]},"published":{"date-parts":[[2019,8,31]]},"assertion":[{"value":"2019-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}